北京若生智能科技有限公司
Drug Database
TA

tamsulosin (tamsulosin WOWTAB / Harnal D)

✓ Approved

Astellas Pharma · ADRA1A · 小分子

什么是 tamsulosin？

tamsulosin 是一种小分子，由Astellas Pharma研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名tamsulosin WOWTAB, Harnal D
公司Astellas Pharma
药物类别小分子
分子靶点ADRA1A
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Astellas Pharma

作用机制

分子靶点

tamsulosin 作用于 1 个分子靶点：

ADRA1Aadrenoceptor alpha 1A (ALPHA1AAR, ADRA1C)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

tamsulosin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Reproductive system and breast disordersBenign prostatic hyperplasia✓ Approved

相关研究文献

PubMedJournal of clinical medicine2026-10-27

Association Between Chronic Tamsulosin Therapy and Intraoperative Hemodynamics During Spinal Anesthesia: A Prospective Observational Study.

Kuvvet Yoldaş Tuba T, Gümüş Nevin Esra NE, Ateşalp Aylin A, Yoldaş Mehmet M

Background: This prospective observational study investigated the association between chronic tamsulosin therapy and intraoperative hemodynamic changes in patients undergoing elective transurethral resection of the prostate (TUR-P) under spinal anesthesia. Methods: Adult patients scheduled for elective TUR-P under spinal anesthesia were prospectively enrolled. Patients receiving long-term tamsulosin therapy comprised the tamsulosin group, whereas those with no history of α1-adrenergic blocker use served as the control group. Hemodynamic variables, including mean arterial pressure (MAP) and heart rate, were recorded before spinal anesthesia and at predefined time points during the first 60 min after spinal anesthesia. Results: A total of 115 patients were analyzed (tamsulosin, n = 56; control, n = 59). Baseline MAP was comparable between groups. The adjusted linear mixed-effects model demonstrated a significant group × time interaction for MAP (F(5, 565.10) = 8.34, p < 0.001). Adjusted between-group MAP differences were -4.9 mmHg (95% CI, -8.8 to -1.0; p = 0.015) at 5 min, -17.0 mmHg (95% CI, -20.2 to -13.8; p < 0.001) at 30 min, and -16.4 mmHg (95% CI, -19.5 to -13.3; p < 0.001) at 60 min. Criteria-defined hypotension occurred in 21/56 (37.5%) patients in the tamsulosin group and 17/59 (28.8%) in the control group (p = 0.32). Conclusions: Chronic tamsulosin therapy was associated with lower intraoperative MAP values during spinal anesthesia, without a statistically significant increase in the incidence of clinically defined hypotension. These findings suggest that chronic tamsulosin use may be associated with a different intraoperative blood pressure response following spinal anesthesia.

PMID 42941492
阅读全文 →
PubMedPolymers2026-10-27

Probing Melatonin's Release Pattern from Oral Solid Dosage Forms Using Synthetic Biopolymers.

Siamidi Angeliki A, Bikiaris Nikolaos N, Protopapa Chrystalla C, Plyta Maria M et al.

Melatonin (N-acetyl-5-methoxytryptamine) (MLT) is a naturally occurring hormone produced endogenously, primarily in the suprachiasmatic nucleus. MLT exhibits a plethora of uses particularly in the treatment of sleep disorders (sleep onset and maintenance). However, due to its short biological half-life, MLT cannot maintain effective plasma concentrations for a prolonged period when it is exogenously taken from immediate-release formulations. The present study aims at developing modified release systems capable of gradually releasing MLT, thereby sustaining its pharmacological effect over eight hours. To this end, modified-release tablets were prepared using new polymeric excipients based on polylactic acid (PLA). Both neat PLA and PLA copolymers with polyethylene glycols (PEGs) of varying molecular weights (PLLA-PEG-PLLA_4000, PLLA-PEG-PLLA_6000, and PLLA-PEG-PLLA_8000) were used, along with other excipients. Certain formulations delivered MLT comparatively fast and may therefore be useful for sleep onset problems, others matched the release behaviour of the marketed product Circadin®, and the rest released the hormone in a more prolonged manner.

PMID 42942691
阅读全文 →
PubMedPharmaceutics2026-10-27

Pharmaceutical 3D Printing Beyond Printability: Polymer Functions, Structural Design, and Predictable Drug Release.

Liu Zhiting Z, Huang Yi Y, Liu Yanpai Y, Huang Rui R et al.

Oral solid dosage forms, due to their mature manufacturing processes and stability, have become the cornerstone of clinical drug therapy. However, fixed dosages, uniform components, and large-scale production may not meet increasingly complex personalized requirements. The emergence of 3D-printed drugs provides a potential solution to this challenge. Drug 3D printing has progressed beyond feasibility verification and is moving toward functional dosage form design. Current research primarily focuses on printability; however, this review integrates printing technology, polymer functionality, structural design, release behavior, and translational requirements, summarizing mainstream printing technologies, including Fused Deposition Modeling (FDM), Direct Ink Writing/Semi-Solid Extrusion (DIW/SSE), Powder Bed Printing (SLS/BJ), and Photopolymerization (SLA/DLP). Polymers are classified according to drug release control functions, illustrating how modulation of porosity, filling density, shell thickness, material partitioning, and spatial drug distribution enables 3D-printed dosage forms with diverse therapeutic functions. These functions include immediate and sustained release, gastric retention, intestinal targeting, and sequential release of multiple components. This review provides guidance for technical selection, structural design, and formulation development of 3D-printed drugs, while highlighting major translational barriers, including limited printable excipients, empirical formulation development, insufficient structure-based release prediction, quality control challenges, and weak clinical evidence. Future progress requires close integration of material, process, structure, and performance, enabling 3D-printed drugs to evolve from individual prototypes into scalable, quality-controllable, and clinically translatable drug delivery systems.

PMID 42942860
阅读全文 →
PubMedPharmaceutics2026-10-27

3D-Printed Gastroretentive Floating Modified-Release Device for Dual Cardiovascular Drug Delivery: Isosorbide Dinitrate and Hydralazine.

Jaiseri Dareena D, Pengnam Supusson S, Opanasopit Praneet P, Suriyaamporn Phuvamin P et al.

Background: Isosorbide dinitrate (ISDN) and hydralazine hydrochloride (HDZ) are dual cardiovascular drugs used to treat heart failure. However, the drugs have limitations such as short plasma half-life, low bioavailability, and potential for tolerance of the nitrate component. To address the need for prolonged drug release, a floating dual-compartment drug delivery system was developed to provide controlled drug release under simulated gastric dissolution conditions. Objectives: This study aimed to develop floating dual-compartment devices (FDCDs) to contain ISDN and HDZ gel and modify drug release under simulated gastric conditions. Methods: The FDCD was designed in a cylindrical shape consisting of an air chamber on the upper part for floating ability, and two compartments for loaded drug gel and controlling the drug release rate. Fused deposition modeling (FDM) was selected to fabricate FDCDs using polylactic acid (PLA) filament. The ISDN formulation varied the ratio of polyvinylpyrrolidone (PVP) to achieve drug release for 12 h. The HDZ formulation was optimized by varying the ratio of PVP and hydroxypropyl methylcellulose (HPMC) to extend drug release at 24 h. Results: The shape dimension and weight variation in the FDCDs showed low standard deviation (SD). FDCDs exhibited immediate floating, resisted overturning, and demonstrated in vitro floating ability for more than 24 h. The formulation ISDN3 at a PVP: drug: water ratio of 5:2:3 exhibited complete release at 12 h, while the formulation of HDZ1 at an HPMC: PVP: drug: water ratio of 0.3:2.5:2:5.2 showed complete release within 24 h. The ISDN3- and HDZ1-loaded FDCDs demonstrated prolonged release behavior, with ISDN and HDZ release profiles showing the best fit to the zero-order and Higuchi models, respectively, based primarily on the coefficient of determination (R2), while root mean square error (RMSE) was used as a complementary measure of fitting error. Conclusions: These findings suggest that the developed dual-drug-loaded FDCD has potential as a dual-drug oral delivery platform for simultaneous delivery of ISDN and HDZ with prolonged drug release characteristics and further development of oral combination drug delivery systems.

PMID 42942809
阅读全文 →
PubMedJournal of neurotrauma2026-10-27

Connexin and Pannexin Channels in Traumatic Spinal Cord Injury: Mechanisms of Secondary Injury and Therapeutic Opportunities.

Toro Carlos A CA, Vásquez Walter W, Michalak Julia J, Woo Rachel R et al.

Traumatic spinal cord injury (tSCI) causes immediate mechanical damage followed by a secondary cascade of excitotoxic, oxidative, metabolic, and inflammatory events that expands tissue loss. Connexin (Cx) and pannexin (Panx) channels are increasingly recognized as potential amplifiers of this secondary injury. This focused review summarizes the structural and biophysical properties of these channels that are relevant to the injured spinal cord, their cellular localization, and the experimental evidence linking Cx43 and Panx1 activity to ATP release, calcium dysregulation, neuroinflammation, tissue loss, neuropathic pain, and functional recovery after tSCI. We also review genetic and pharmacologic studies of channel inhibition and discuss the limited but emerging evidence for Cx-mediated signaling in paralyzed skeletal muscle. Evidence is strongest for astrocytic Cx43 hemichannels, whereas the contribution of Panx1 after tSCI remains promising but less completely defined. Throughout, we distinguish findings demonstrated directly after tSCI from mechanisms inferred from other tissues or disease models and identify priorities for translational research.

PMID 42934936
阅读全文 →
PubMedBioengineering (Basel, Switzerland)2026-10-27

Interaction Between Implant Macrogeometry and Osteotomy Preparation on Immediate Mechanical Fixation and Regional Thread Alterations: An Ex Vivo Biomechanical Study.

Banegas-Cano Almudena A, Sánchez-Pérez Arturo A, Jornet-García Alfonso A, Montoya-Carralero José María JM et al.

Immediate implant mechanics may depend on the interaction between implant macrogeometry and osteotomy preparation, but their combined influence on complementary measures of immediate fixation and regional thread alterations remains insufficiently characterized. This ex vivo study evaluated two implant macrogeometries and four osteotomy techniques in 80 bovine rib specimens (n = 10 per group). Reverse torque resistance remained the primary mechanical outcome; prospectively recorded insertion torque and resonance frequency analysis (implant stability quotient [ISQ]) were incorporated in the revision as complementary immediate mechanical outcomes. Thread alterations were assessed qualitatively after removal in the cervical, body, and apical regions. Insertion torque was significantly influenced by macrogeometry and preparation technique, without a significant interaction. Reverse torque resistance showed significant effects of macrogeometry, preparation technique, and their interaction (all p < 0.001). ISQ showed a significant macrogeometry-by-technique interaction. Insertion torque correlated strongly with reverse torque resistance (r = 0.645, p < 0.001), whereas ISQ showed a more moderate association (r = 0.370, p < 0.001), supporting related but non-interchangeable mechanical constructs. Cervical alterations were mainly associated with undersized drilling, whereas apical alterations occurred predominantly in the Quattro design; none were observed in the implant body. External surface temperature showed no overall change or consistent technique-dependent increase. Under these experimental conditions, implant macrogeometry and osteotomy preparation acted as interdependent determinants of immediate mechanical behavior and were associated with distinct regional patterns of post-removal, visually detectable thread alterations.

PMID 42938962
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多tamsulosin